Qube Research & Technologies LTD Catalyst Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

$62.3 Billion
Q2 2024

A detailed history of Qube Research & Technologies LTD transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 128,734 shares of CPRX stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

128,734

Previous 90,250 42.64%

Holding current value

$2.75 Million

Previous $1.44 Million 38.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.68 - $16.92 $564,945 - $651,149	38,484 Added 42.64%	128,734 $1.99 Million
Q1 2024 May 14, 2024	BUY	$13.18 - $17.11 $1.19 Million - $1.54 Million	90,250 New	90,250 $1.44 Million
Q3 2023 Nov 13, 2023	BUY	$11.69 - $15.02 $754,916 - $969,961	64,578 New	64,578 $754,000
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $1.49 Million - $2.38 Million	121,873 New	121,873 $2.27 Million
Q2 2022 Aug 15, 2022	SELL	$6.23 - $8.57 $193,572 - $266,278	-31,071 Reduced 20.21%	122,638 $860,000
Q1 2022 May 09, 2022	SELL	$5.31 - $8.31 $130,684 - $204,517	-24,611 Reduced 13.8%	153,709 $1.27 Million
Q4 2021 Feb 01, 2022	BUY	$5.21 - $7.45 $488,791 - $698,944	93,818 Added 111.02%	178,320 $1.21 Million
Q3 2021 Nov 12, 2021	BUY	$4.85 - $6.04 $195,154 - $243,037	40,238 Added 90.9%	84,502 $448,000
Q2 2021 Aug 13, 2021	BUY	$4.29 - $6.05 $189,892 - $267,797	44,264 New	44,264 $255,000
Q2 2020 Aug 14, 2020	SELL	$3.48 - $5.05 $118,403 - $171,821	-34,024 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $88,802 - $177,265	34,024 New	34,024 $131,000

Others Institutions Holding CPRX

# of Institutions

285

Shares Held

96.6M

Call Options Held

29.2K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.2B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Catalyst Pharmaceuticals, Inc. Transaction History